As an entrepreneur, Thomas Smeenk is Co-Founder, President, and CEO of Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF), a phase III clinical-stage-facing biotechnology company. Thomas is focused on commercializing ACP-01. The subject of 11 peer-reviewed publications, seven clinical studies of 318 subjects, and administered to 498 individuals safely, ACP-01 is demonstrated to be clinically relevant in five Phase I trials, one multicenter Phase II trial, and one retrospective study of 54 subjects treated for two forms of cardiomyopathy (ICM + DCM).
A strategic operator, financier, and dealmaker, Thomas has simultaneously structured lawful, scalable commercialization pathways in The Bahamas, Florida, and Canada, leveraging Bahamian regenerative medicine law, Florida’s SB-1768, and Canada’s First Nations’ sovereign authority to deliver healthcare on treaty land, tax-exempt.
Today, Thomas’ focus is twofold: combining commercially generated real-world treatment evidence with commercially generated longitudinal Phase I data for regulatory approvals; and building Hemostemix through acquisitions of private cardiology and interventional podiatry practices to vertically integrate and profitably deliver a validated autologous stem cell therapy globally.